Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy —Real-World Clinical Impressions and Comparative Review of the Literature

Conclusion: Our real-world clinical series confirms an objective response for about every fifth patient, promising OS and a low incidence for severe adverse events (≥Grade 3).
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research